Skip to main content
ADPT logo

ADPT · Adaptive Biotechnologies Corp

Track ADPT — free
$24.74 +0.28 (+1.14%) At close · Aug 14
Market Cap
$3.95B
Shares
159.60M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$24.74 Open$24.27 Day$24.00–24.95 Since split$21.86–25.45 Avg vol since split · 23d2.7M Short int12.5M · 7.8% float · 4.4d Short vol40% Last earningsJul 29, 2026 DataJul 2026–Aug 2026 Filing10-Q · Aug 4

Raw chart and full-history price indicators begin at the captured split on Jul 15, 2026; bars on opposite sides are not compared.

The closing range begins at the captured split on Jul 15, 2026.

Up next

Next earnings call
Oct 28, 2026 Est · unconfirmed · in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
filed Aug 4, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Neutral
      SellHoldBuy
      Technical Neutral Momentum Limited Sentiment Neutral Fundamentals Strong Quant / Vol High
      Market backdrop VIX 14.3 · calm Equity put/call 0.52
      Technical
      price trend
      Neutral
      50 / 200-day cross No cross
      RSI (14) 56
      neutral
      52-week position 80%
      mid-range
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Limited
      Not enough data for a confident read.
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50/200-day averages unavailable
      Institutional flow Flat
      0% holders QoQ · +51 funds added
      Insider flow Distributing
      Net -$40.6K over 90 days · 100% sells
      Short interest Rising
      7.83% of float · ▲ +9.6% MoM · 4.4 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      298 holders — near 3-yr high, broad support
      Squeeze score 70
      high risk · 0–100
      Fundamentals
      Strong
      Revenue growth +55%
      Y/Y
      EPS growth +64%
      Y/Y
      Free cash flow $-48.9M
      Balance sheet $60.7M
      net debt
      Quant / Vol
      risk profile
      High
      Volatility 57%
      annualized · 1-yr
      Max drawdown −7%
      past year
      ATR 5.2%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the 8-K filed Jul 29, 2026
      MRD revenue · full year 2026 $268M – $278M
      Prior guidance period ended · from the 8-K filed Nov 5, 2025
      MRD business revenue · full year 2025 $202M – $207M
      Total company cash burn · full year 2025 $45M – $50M
      Total company operating expenses, including cost of revenue · full year 2025 $335M – $340M

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Neutral
      0 · 4 · 0
      50 / 200-day cross
      No cross Neutral
      RSI (14)
      56 Neutral
      52-week position
      80% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bearish · 2 of 6
      Trend (MA cross) No cross
      50/200-day averages unavailable
      Institutional flow Flat
      0% holders QoQ · +51 funds added
      Insider flow Distributing
      Net -$40.6K over 90 days · 100% sells
      Short interest Rising
      7.83% of float · ▲ +9.6% MoM · 4.4 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      298 holders — near 3-yr high, broad support
      Price context
      position in its range since split · 2026-07-15
      Range low $22 Now $25 · 80% Range high $25

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      clonoSEQ tests delivered 105,587 Full Year 2025

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Diagnostics & Research — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      ADPT
      Adaptive Biotechnologies Corp
      this stock
      $3.95B +54.8% 7.8%
      TMO
      Thermo Fisher Scientific Inc.
      $217.52B +1.5% +14.5% 31.7 1.3%
      DHR
      Danaher Corp /De/
      $142.32B -11.6% +8.5% 35.9 1.7%
      NTRA
      Natera, Inc.
      $44.67B +35.3% -2.8% 3.0%
      IDXX
      Idexx Laboratories Inc /De
      $43.41B -18.6% +10.4% 38.7 2.4%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      298
      % held
      25.4%
      Net QoQ
      +2.5M sh
      Top holder
      VIKING GLOBAL INVESTORS LP
      Held Float
      View
      Held by Funds
      Fund positions
      287
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      12.5M
      Days to cover
      4.4d
      Change
      +1.1M sh
      View
      Short Volume
      Short vol %
      40%
      As of
      Aug 14, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      3.1K
      Value
      $66.3K
      As of
      Jun 30, 2026
      View
      Off-Exchange
      Off-exchange %
      39.9%
      Week of
      Jul 6, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$40.6K
      Buyers / Sellers
      0 / 1
      Buyers Sellers
      View
      Financials
      Financials
      Revenue (FY)
      $277.0M
      Net income (FY)
      $-59.5M
      EPS diluted
      $-1.56
      View
      Filings
      SEC Filings
      Latest
      10-Q
      Filed
      Aug 4, 2026
      This year
      12
      View
      Proposed Sales
      Value
      $74.8K
      Shares
      3.0K
      Filed
      Aug 10, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Jul 29, 2026
      View

      Performance

      Raw-price comparisons begin at the captured split on Jul 15, 2026; windows that need an earlier baseline remain unavailable.

      5D 20D 120D MTD YTD
      ADPT -0.8% +7.9% +9.6%
      SPY +0.4% +4.5% +13.8% +3.9% +13.9%
      vs SPY -1.2% +3.5% +5.7%
      Key facts CIK 1478320 CUSIP 00650F109 13F (30d) 286 filings 282 filers Visit website Investor relations